EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES
Remo Panaccione(University of Calgary), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Mary Ellen Frustaci(Johnson & Johnson (United States)), Zijiang Yang(Henan Medical University), Tadakazu Hisamatsu(Kyorin University), Jane M. Andrews(Health Net), Julián Panés(Hospital Clínic de Barcelona), Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Rian Van Rampelbergh(Janssen (Belgium)), David T. Rubin(University of California System), Geert D’Haens(Amsterdam University Medical Centers), Natalie A. Terry(Janssen (United States)), Jacqueline Yee(Johnson & Johnson (United States)), Walter Reinisch(Medical University of Vienna), Anita Afzali(University of Cincinnati Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Kitty Y. Wan(Johnson & Johnson (Switzerland)), Leonardo Salese(Johnson & Johnson (United States))
Cited by 28
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k